Communiqués Vera Therapeutics, Inc.

Actions

VERA

US92337R1014

Temps réel estimé Cboe BZX Autres places de cotation 19:00:19 12/06/2024			Varia. 5j.	Varia. 1 janv.
38,46 ^USD	+0,09 %		-7,21 %	+148,44 %

28/05	Vera Therapeutics obtient de la FDA la désignation de thérapie innovante pour le traitement de la néphropathie à l'immunoglobuline A	MT
28/05	Vera Therapeutics Inc. reçoit de la FDA américaine la désignation de thérapie innovante pour l'atacicept dans la néphropathie à immunoglobuline A (IgAN)	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors	11/06	GL
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/06	GL
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	07/06	GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)	28/05	GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)	28/05	AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress	25/05	AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress	25/05	GL
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	09/05	GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K	09/05	PU
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	02/04	GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress	02/04	AQ
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03	GL
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03	AQ
Developing a new treatment paradigm for IgAN	14/03	AQ
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference	28/02	GL
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	02/02	GL
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock	01/02	GL
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock	30/01	GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock	29/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Vera Therapeutics, Inc.

Actions

VERA

US92337R1014

Communiqués

Filtres